quinidine has been researched along with indacaterol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| He, X; Hu, B; Li, C; Ma, Y; Wang, J; Wang, Y; Xue, W; Zhang, F; Zhang, T | 1 |
2 other study(ies) available for quinidine and indacaterol
| Article | Year |
|---|---|
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
Topics: A549 Cells; Carvedilol; Cell Proliferation; Cell Survival; Cytochrome P-450 CYP1B1; Density Functional Theory; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |